[go: up one dir, main page]

SG11201603376UA - Nmda receptor modulators and prodrugs, salts, and uses thereof - Google Patents

Nmda receptor modulators and prodrugs, salts, and uses thereof

Info

Publication number
SG11201603376UA
SG11201603376UA SG11201603376UA SG11201603376UA SG11201603376UA SG 11201603376U A SG11201603376U A SG 11201603376UA SG 11201603376U A SG11201603376U A SG 11201603376UA SG 11201603376U A SG11201603376U A SG 11201603376UA SG 11201603376U A SG11201603376U A SG 11201603376UA
Authority
SG
Singapore
Prior art keywords
prodrugs
salts
nmda receptor
receptor modulators
nmda
Prior art date
Application number
SG11201603376UA
Inventor
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of SG11201603376UA publication Critical patent/SG11201603376UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126Tetrapeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SG11201603376UA 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof SG11201603376UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28
PCT/US2014/062367 WO2015065891A1 (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Publications (1)

Publication Number Publication Date
SG11201603376UA true SG11201603376UA (en) 2016-05-30

Family

ID=53004986

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810496XA SG10201810496XA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof
SG11201603376UA SG11201603376UA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201810496XA SG10201810496XA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Country Status (15)

Country Link
US (2) US9745342B2 (en)
EP (2) EP3062810A4 (en)
JP (1) JP6603668B2 (en)
KR (1) KR20160077153A (en)
CN (2) CN105764522A (en)
AU (2) AU2014342624A1 (en)
BR (1) BR112016009443A8 (en)
CA (1) CA2928701A1 (en)
CL (2) CL2016001001A1 (en)
IL (1) IL245302B (en)
MX (2) MX378668B (en)
RU (1) RU2016119830A (en)
SA (1) SA516371037B1 (en)
SG (2) SG10201810496XA (en)
WO (1) WO2015065891A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3598971B1 (en) 2013-01-22 2024-03-20 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
PL3416631T3 (en) * 2016-08-11 2019-11-29 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
CN116082461B (en) * 2022-10-14 2023-11-14 浙江大学 Small molecular peptide with antibacterial activity and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263858A1 (en) 2004-09-14 2009-10-22 Shionogi & Co., Ltd. Process for synthesis of mucin-type peptides and muc1-related glycopeptides
WO2008076904A1 (en) * 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981999B2 (en) * 2007-02-23 2011-07-19 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR101769999B1 (en) * 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Nmda receptor modulators and uses thereof
AU2009294875C1 (en) * 2008-09-22 2015-05-14 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
KR101692275B1 (en) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
CN102933226A (en) * 2010-02-11 2013-02-13 西北大学 Secondary structure stabilized nmda receptor modulators and uses thereof
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Also Published As

Publication number Publication date
RU2016119830A (en) 2017-12-04
CA2928701A1 (en) 2015-05-07
MX2016005510A (en) 2017-01-06
US10590167B2 (en) 2020-03-17
RU2016119830A3 (en) 2018-07-02
MX2021000029A (en) 2021-03-25
MX378668B (en) 2025-03-10
AU2014342624A1 (en) 2016-06-02
CN112321678A (en) 2021-02-05
EP3062810A4 (en) 2017-05-03
US20160244485A1 (en) 2016-08-25
US9745342B2 (en) 2017-08-29
IL245302A0 (en) 2016-06-30
JP6603668B2 (en) 2019-11-06
KR20160077153A (en) 2016-07-01
JP2016537413A (en) 2016-12-01
BR112016009443A8 (en) 2020-03-24
IL245302B (en) 2020-05-31
SG10201810496XA (en) 2018-12-28
CL2020002247A1 (en) 2021-02-05
CL2016001001A1 (en) 2016-12-16
US20180127466A1 (en) 2018-05-10
SA516371037B1 (en) 2018-05-16
EP3564256A1 (en) 2019-11-06
WO2015065891A1 (en) 2015-05-07
AU2020201109A1 (en) 2020-03-05
CN105764522A (en) 2016-07-13
EP3062810A1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
IL240166A0 (en) Spiro-lactam nmda receptor modulators and uses thereof
IL240164A0 (en) Spiro-lactam nmda receptor modulators and uses thereof
IL240163B (en) Spiroa-lactam nmda receptor modulators and uses thereof
IL240162A0 (en) Spiro-lactam nmda receptor modulators and uses thereof
IL240165A0 (en) Spiro-lactam nmda receptor modulators and uses thereof
GB2517497B (en) Improved Supply Modulator
EP3058276A4 (en) A dispersion apparatus
SI3066091T1 (en) Nmda antagonist prodrugs
EP2977966A4 (en) Paper currency-processing device
IL245302B (en) Nmda receptor modulators and prodrugs, salts, and uses thereof
GB2520280B (en) Stirrup
GB201321601D0 (en) Modulator
GB201318444D0 (en) Printing
GB201312727D0 (en) Modulators
GB201416091D0 (en) Device For Forming Brunnian Links
PL3049570T3 (en) Dispersion for producing abrasion-resistant surfaces
GB201316031D0 (en) Alignment member
HUP1300504A2 (en) Sorafenib salts
TH1601002410A (en) NMDA receptor modulators and prodrugs, salts, and their uses
GB201318298D0 (en) Modulators
GB201317988D0 (en) Modulators
GB201304473D0 (en) Modulators
TWM476794U (en) Cheval-de-frise projection device
GB201305949D0 (en) Sternotomy spacing device
AU2013904005A0 (en) A Dispersion Apparatus